Connect with us

Business

Tallest South Bristol tower approved after councillors warned they could lose an appeal

Published

on

Business Live

Scheme received hundreds of objections from residents and local heritage and planning groups

The proposed Princess Street tower seen from the New Cut

The planned Princess Street tower seen from the New Cut(Image: Liz Lake Associates)

Controversial plans for South Bristol’s tallest ever building have been approved after councillors were told they would lose an appeal, costing city taxpayers £1million.

Advertisement

The city council’s planning committee granted permission for 434 flats, of which one-fifth will be ‘affordable’, and 400 student beds, in four blocks including a 23-storey tower on a site south of Princess Street between Victoria Park and the New Cut.

Members vetoed the development in January amid concerns about the height and number of apartments, along with harm to views of important buildings, and asked officers who had recommended giving the go-ahead to come back with reasons for refusal.

But despite 468 objections from residents and local heritage and planning groups, the updated report to the committee said rejecting the scheme would not withstand an appeal from developers Galliard Apsley, and the advice remained to approve.

Councillors voted 6-3 in favour after a marathon three-hour debate on Wednesday evening (March 11).

Advertisement

Among those who objected were Historic Buildings and Places, Avon Gardens Trust, Bristol Civic Society, the Conservation Advisory Panel, Totterdown Residents Environmental and Social Action (TRESA), Windmill Hill and Malago Planning Group, BS3 Planning Group, Victoria Park Action Group, Windmill Hill City Farm, Learning Partnership West School, St Mary Redcliffe Primary School, and Structural Soils.

Historic England did not object but expressed concerns about the impact on views of St Mary Redcliffe.

During public forum, Cllr Ed Plowden (Green, Windmill Hill) said: “The officer report fails to respect this committee’s instruction to write a report that justifies refusal.

“The committee should reject this report, renew its instructions and then insist on a report that does not sabotage its own decision.”

Advertisement

Former Bristol mayor George Ferguson, an architect and adviser to Historic England, said: “Of course we support more homes.

“We remain strongly opposed [to the plans].

“I ask you to stick to your guns and refuse.”

He said a late engagement exercise undertaken by the developers, which resulted in 36 letters of support and just four against, was ‘suspicious’ and appeared to have been written by ‘hostages’.

Advertisement

Mr Ferguson said the development ‘fails dismally on design, environment, heritage, landscape, and social grounds’.

He said: “It is quite wrong for the officers to try to override the democratic process in this way by threatening a lost appeal, especially when there are a host of reasons why this scheme should never have seen the light of day.”

Asked by Cllr Andrew Varney (Lib Dem, Brislington West) what the financial risk was to the authority if the plans were refused, Bristol City Council chief planning officer Simone Wilding said: “I would estimate the costs awarded against us to be in the region of three-quarters of a million pounds.

“Plus on top of that, if we chose to defend, we would have our own costs, so in total we are probably looking at about £1million.

Advertisement
The planned Princess Street tower seen from Victoria Park

The proposed Princess Street tower seen from Victoria Park(Image: Liz Lake Associates)

“There would be a high risk of costs being awarded against us.”

But Cllr Guy Poultney (Green, Cotham) said: “We’ve now had a figure put on the table which is not in the report, and is not something that can be substantiated or challenged.

“The one thing we do know is that we’re not meant to take it into account at all.”

He said the law stated that the cost of an appeal was not a material planning consideration.

Advertisement

Cllr Poultney said: “This committee should be really clear that it asked officers to go away and provide robust reasons for refusal.

“I hate to say it but that time has been used to try not to build those reasons for refusal but to strengthen those reasons to grant.

“If that’s the case, this should be the final nail in the coffin of this cooling-off policy because it is clearly not doing the job that councillors agreed in the first place.”

Cllr Serena Ralston (Green, Clifton Down) said: “We have not been given much choice in the matter – the officer report has been tilted in favour of development, it doesn’t seem a very democratic process.

Advertisement

“We’re under the cosh here. There is no other choice but to approve it.

“I am very uncomfortable because this is not a high-quality development.”

Committee chairman Cllr Rob Bryher (Green, St George West) said: “I don’t like the height of this building, I don’t like the design.

READ MORE: Bid for 400 homes near M5 clears first hurdleREAD MORE: Michelin-starred Midlands chef Aktar Islam to open new restaurant in Bristol

Advertisement

“I don’t know whether it’s better to hear the substantial community voices who have made very clear your objections to it, or whether to go with the very clear policy guidance within the constraints of the system that will continually ask us to do these things in planning communities over the next few years and decades.

“To be honest, it’s part of the reason I’m going to give this up [as committee chairman].

“It’s just too demoralising. I don’t like making these decisions any more.”

But Cllr Varney said: “Bristol is not a museum piece, it’s a commercial, dynamic city – it changes.

Advertisement

“Yes, the tallest building is tall but it is by no means the tallest building that’s been consented in Bristol.

“We have buildings with planned consent of 28 storeys, and that is still quite small-fry compared to other comparable cities around the UK.

“Yes, there will be an impact on views but it is not as important as the need to deliver housing.

“We have 20,000 families on the housing waiting list.

Advertisement

“It’s a disgrace that we are even considering not approving this scheme that will deliver housing for people on the housing waiting list.

“What is more important – a view or a house? I am voting for a house.”

Cllr Richard Eddy (Conservative, Bishopsworth) said the project would provide more than 800 homes and millions of pounds of developer contributions for improvements to transport, public spaces, a medical facility and employment space, including food and drink outlets.

He said: “It is a scheme worthy of support. I beg members to support this.”

Advertisement

Cllr Patrick McAllister (Green, Hotwells & Harbourside) said: “We have a crippling housing crisis.

“I don’t like the tower block but homelessness is uglier than a tower block and I don’t see where this doesn’t get built through an appeal where the council will be subject to substantial costs, but I’m not happy about it.”

Voting in favour were Labour Cllrs Lisa Durston, Kye Dudd and Louis Martin, Cllr Eddy, Cllr Varney and Cllr McAllister, while Green Cllrs Poultney, Bryher and Ralston were against.

To find all the planning applications, traffic diversions, road layout changes, alcohol licence applications and more in your community, visit the Public Notices Portal.

Advertisement
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

TrumpRx expands with 2 new drug makers offering prescription discounts

Published

on

TrumpRx expands with 2 new drug makers offering prescription discounts

EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned.

As early as today, Amgen and GSK will be added to the list of prescription drug manufacturers offering discounts on the government website. That makes a total of 54 prescription medications from six pharmaceutical companies that have signed on to the most-favored-nation pricing under pressure from President Donald Trump and the threat of tariffs.

Advertisement

Amgen will offer medication on the website that cuts 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

President Donald Trump and Dr. Mehmet Oz at an event.

President Donald Trump speaks as Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz looks on during an event on drug pricing in the South Court Auditorium on the White House campus Feb. 5, 2026, in Washington, D.C. (Nathan Howard/Getty Images)

The company plans to list Aimovig and Repatha for discounts of 62%.

GSK will discount Incruse at 55% of the retail price. The drug treats COPD and will be listed at $159.

Advertisement

GSK also plans to list Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%.

Ticker Security Last Change Change %
AMGN AMGEN INC. 366.21 -1.58 -0.43%
GSK GSK PLC 53.39 -0.89 -1.64%

“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” White House spokesman Kush Desai told FOX Business. 

“TrumpRx.gov is just the beginning, however, as Americans are set to (receive) even greater drug pricing discounts, lower insurance premiums and more transparency when Congress passes President Trump’s Great Healthcare Plan.”

A pharmacy tech pulls medication from a shelf inside a pharmacy

Amgen will offer medication on the website that cuts 80% off the retail price. (George Frey/Bloomberg via Getty Images)

The Pharmaceutical Research and Manufacturers of America represents major drug companies.

Advertisement

CEO Stephen Ubl believes “Government-imposed most-favored-nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients.

HOUSE GOP SEEKS OFF-RAMP TO SKY-HIGH HEALTH INSURANCE COSTS FOR MILLIONS OF AMERICANS

“These policies would siphon billions from American R&D, slow the pace of cures and increase reliance on China for future innovation.”

An image of medication at a Walgreens pharmacy.

GSK will discount Incruse at 55% of the retail price. (Jeffrey Greenberg/Universal Images Group via Getty Images)

The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs.

Advertisement

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Continue Reading

Business

Form 13D/A Health Catalyst For: 13 March

Published

on


Form 13D/A Health Catalyst For: 13 March

Continue Reading

Business

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference – Slideshow

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference – Slideshow

Continue Reading

Business

Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Operator

Greetings, and welcome to Vaxart’s Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the webcast over to David Carey, Finn Partners.

Advertisement

David Carey
Finn Partners, Inc.

Good afternoon, and welcome to today’s call. Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James S. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company’s future cash runway, ability to regain compliance with NASDAQ listing standards or raise capital if such listing is regained, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart’s most recently filed annual report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update

Advertisement
Continue Reading

Business

Dan Ives Is Stepping Down as Eightco Chairman

Published

on

Dan Ives Is Stepping Down as Eightco Chairman

Dan Ives Is Stepping Down as Eightco Chairman

Continue Reading

Business

Thomson Reuters Files Documents for Proposed Return of Capital and Share Consolidation Transactions

Published

on

Cision

TORONTO, March 13, 2026 /PRNewswire/ — Thomson Reuters (TSX/Nasdaq: TRI) today filed its management proxy circular and related documents in connection with the upcoming special meeting at which shareholders will be asked to approve the proposed return of capital and share consolidation transactions, among other items. The management proxy circular and related documents are available online and for pick-up, as set out below.

The transactions consists of a special cash distribution of US$605 million in the aggregate, or approximately US$1.36 per common share (estimated based on the number of common shares issued and outstanding as of the record date and assuming no shareholders opt-out of the return of capital) followed by a consolidation of outstanding common shares (or “reverse stock split”) on a basis that is proportional to the special cash distribution. The share consolidation ratio will be based on the volume weighed average trading price of the common shares on the Nasdaq Stock Market LLC (“Nasdaq”) for the five trading days immediately prior to the return of capital becoming effective.

The proposed return of capital is intended to distribute cash on a basis that is generally expected to be tax-free for Canadian tax purposes. Shareholders who are taxable in a jurisdiction outside of Canada (including taxable U.S. resident shareholders and others) (“Eligible Opt-Out Shareholders”) will be able to opt out of the return of capital. This right to opt out is being provided to those shareholders because in jurisdictions other than Canada the tax consequences of not participating in the return of capital may be preferable to those associated with participating in the return of capital. If an Eligible Opt-Out Shareholder chooses to opt out, it will not receive the cash distribution and will continue to hold the same number of shares that it currently holds.

Details of the transaction (including information regarding the opt-out right) are described in the management proxy circular and related materials, which are available on thomsonreuters.com in the “Investor Relations” section. The documents were filed with the Canadian securities regulatory authorities on SEDAR+ and are available at www.sedarplus.com. The documents will also be furnished to the U.S. Securities and Exchange Commission through EDGAR and when filed, will be available at www.sec.gov. The documents will also be available for pick-up, free of charge, at Computershare Investor Services Inc.’s offices in Toronto, Montreal, Vancouver and Calgary. Please contact Computershare Investor Services Inc. using the phone numbers set out below for the addresses of those offices.

Advertisement

The special meeting of shareholders will be held on Tuesday, April 28, 2026 at 9:00 a.m. EDT (changed from the original planned time of 12:00 p.m.). The meeting will be a webcast on thomsonreuters.com in the “Investor Relations” section. Holders of Thomson Reuters common shares as of 5:00 p.m. EDT on March 6, 2026 are entitled to vote at the meeting.

Registered shareholders who have questions or need assistance voting their shares may contact Computershare Investor Services Inc. at 1.800.564.6253 (toll-free in Canada and the U.S.) or at 1.514.982.7555 (outside Canada and the U.S.). Non-registered shareholders who hold their shares indirectly through an intermediary (such as an investment dealer, stock broker, bank, trust company or other nominee) should contact their intermediary if they have questions or need assistance. Shareholders who have questions or need assistance may also contact D.F. King & Co., Inc., who is acting as Information Agent for the transaction, at 1.800.967.5068 (toll-free in Canada and the U.S.) or at 1.212.561.5870 (outside Canada and the U.S., banks, brokers and collect calls) or at the following email address: tri@dfking.com.

About Thomson Reuters

Thomson Reuters (TSX/Nasdaq: TRI) informs the way forward by bringing together the trusted content and technology that people and organizations need to make the right decisions. The company serves professionals across legal, tax, audit, accounting, compliance, government, and media. Its products combine highly specialized software and insights to empower professionals with the data, intelligence, and solutions needed to make informed decisions, and to help institutions in their pursuit of justice, truth and transparency. Reuters, part of Thomson Reuters, is the world’s leading provider of trusted journalism and news. For more information, visit thomsonreuters.com.

Advertisement

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this news release are forward-looking within the meaning of applicable Canadian and U.S. securities laws, including the Private Securities Litigation Reform Act of 1995. These statements relating to the return of capital and share consolidation transactions and the anticipated tax treatment for shareholders participating in the return of capital and those opting out. These forward-looking statements are based on certain assumptions, including shareholder approval of the transactions, and reflect our company’s current expectations. As a result, forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the risk factors discussed in materials that Thomson Reuters from time to time files with, or furnishes to, the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. There is no assurance that the return of capital and share consolidation transactions will be completed or that other events described in any forward-looking statement will materialize. Except as may be required by applicable law, Thomson Reuters disclaims any obligation to update or revise any forward-looking statements.

CONTACTS

MEDIA
Zoe ZanettosDirector, Corporate Affairs
+1 647 202 8948
zoe.zanettos@thomsonreuters.com 

Advertisement

INVESTORS
Gary E. Bisbee, CFA
Head of Investor Relations
+1 646 540 3249
gary.bisbee@thomsonreuters.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thomson-reuters-files-documents-for-proposed-return-of-capital-and-share-consolidation-transactions-302713835.html

SOURCE Thomson Reuters

Continue Reading

Business

Iridex signs lease for new San Jose headquarters with 90-month term

Published

on


Iridex signs lease for new San Jose headquarters with 90-month term

Continue Reading

Business

Nancy Guthrie Update: Any Major Breakthrough In Investigation?

Published

on

Nancy Guthrie

The search for Nancy Guthrie, the 84-year-old mother of NBC “Today” show co-anchor Savannah Guthrie, entered its 41st day Friday with authorities emphasizing that the February abduction from her Tucson-area home appears to have been targeted, though no suspect has been publicly identified.

Continue Reading

Business

Progyny issues notice of settlement for derivative action regarding director pay

Published

on


Progyny issues notice of settlement for derivative action regarding director pay

Continue Reading

Business

Form 4 Better Home & Finance Holding Co For: 13 March

Published

on


Form 4 Better Home & Finance Holding Co For: 13 March

Continue Reading

Trending

Copyright © 2025